2020 年第 4 期 第 15 卷

甲磺酸阿帕替尼片联合替吉奥和奥沙利铂治疗晚期胃癌的效果与安全性

Efficacy and safety of apatinib mesylate tablets combined with tegafur, gimeracil and oteracil potassium capsules and oxaliplatin in treatment of advanced gastric cancer

作者：郭军王娜刘登湘孙雅薇靳毅张菊萍邱鹏

英文作者：Guo Jun Wang Na Liu Dengxiang Sun Yawei Jin Yi Zhang Juping Qiu Peng

单位：河北省邢台市人民医院肿瘤内科054031 

英文单位：Department of Oncology Xingtai People′s Hospital Hebei Province Xingtai 054031 China

关键词：晚期胃癌；甲磺酸阿帕替尼片

英文关键词：Advancedgastriccancer；Apatinibmesylatetablets

• 摘要：

• 【摘要】目的    探讨甲磺酸阿帕替尼片联合替吉奥和奥沙利铂治疗晚期胃癌的效果与安全性。方法    选择2015年7月至2016年7月河北省邢台市人民医院收治的晚期胃癌患者60例，按照随机数字表法分为对照组和观察组，各30例。对照组患者给予奥沙利铂注射液和替吉奥胶囊治疗；观察组患者在对照组基础上加用甲磺酸阿帕替尼片治疗。比较2组患者临床疗效、不良反应发生情况和随访5年生存情况。结果    观察组患者疾病缓解率及疾病控制率均明显高于对照组［46.7%(14/30)比13.3%(4/30)、73.3%(22/30)比33.3%(10/30)］，差异均有统计学意义（均P＜0.001）。2组患者主要不良反应发生情况比较，差异均无统计学意义（均P＞0.05）。随访48、60个月，观察组生存率均高于对照组［90.0%(27/30)比70.0%(21/30)、86.7%(26/30)比67.7%(20/30)］，差异均有统计学意义（均P＜0.05）。结论    甲磺酸阿帕替尼片联合替吉奥和奥沙利铂治疗晚期胃癌的临床效果优于替吉奥联合奥沙利铂，且不增加不良反应。

• 【Abstract】Objective    To investigate the efficacy and safety of apatinib mesylate tablets combined with tegafur, gimeracil and oteracil potassium capsules and oxaliplatin in treatment of advanced gastric cancer. Methods    Sixty patients with advanced gastric cancer admitted to Xingtai People′s Hospital from July 2015 to July 2016 were randomly divided into control group and observation group, with 30 cases in each group. The control group was treated with oxaliplatin mannitol for injection and tegafur, gimeracil and oteracil potassium capsules. The observation group took apatinib mesylate tablets on the basis of control group. Clinical efficacy, adverse reactions and 5-year survival rate were analyzed. Results    Remission rate and control rate in the observation group were significantly higher than those in the control group［46.7%(14/30) vs 13.3%(4/30), 73.3%(22/30) vs 33.3%(10/30)］(both P＜0.001). There was no significant difference in the incidence of major adverse reactions between groups(P＞0.05). The 48- and 60-month survival rates in the observation group were significantly higher than those in the control group ［90.0%(27/30) vs 70.0%(21/30), 86.7%(26/30) vs 67.7%(20/30)］(both P＜0.05). Conclusion    Apatinib mesylate tablets combined with tegafur, gimeracil and oteracil potassium capsules and oxaliplatin are safe and effective in treating advanced gastric cancer.